SNCA and Parkinson disease: In two independent cohorts from the Swedish BioFinder study, higher baseline levels of total α-synuclein were associated with greater progression of motor symptoms over two years [81] and a longitudinal increase of total α-synuclein was found after two-year follow-up in PD patients with longer disease duration (>5 years) [51].